Chandra Bhagat Pharma Reports Strong FY26 Growth, Plans Capital Infusion

Revenue from Operations: ₹116.27 crore
Profit After Tax: ₹3.05 crore

Reader Takeaway: Strong profit turnaround and planned capital raise for vaccine market entry.

What just happened

Chandra Bhagat Pharma Ltd has announced robust financial results for the fiscal year 2025-26, with Revenue from Operations increasing by 30.93% to ₹116.27 crore from ₹88.81 crore in the previous year. The company's Profit After Tax (PAT) saw a substantial surge of 255.15%, reaching ₹3.05 crore compared to ₹0.86 crore in FY 2024-25. The Board of Directors has proposed raising ₹29.04 crore by issuing 66 lakh convertible warrants at ₹44 per warrant to promoters and non-promoters on a preferential basis. The authorized share capital is also being increased from ₹8.50 crore to ₹15 crore.

Why this matters

This performance signifies a strong turnaround for Chandra Bhagat Pharma, demonstrating improved sales and significant profit expansion. The proposed capital raise of ₹29.04 crore signals management's commitment to funding future growth initiatives, particularly its ambition to enter the vaccine market. This strategic move, along with plans for a new manufacturing plant, could position the company for future expansion.

The backstory

In FY 2024-25, the company reported Revenue from Operations of ₹88.81 crore and a PAT of ₹0.86 crore. The current fiscal year shows a considerable improvement on both fronts, indicating successful execution of their core business strategy in pharmaceutical formulations and API products.

What changes now

The company will proceed with the preferential issuance of warrants, subject to necessary approvals. The funds raised will be utilized for working capital requirements and general corporate purposes, and potentially for planned expansions such as establishing a manufacturing plant and entering the vaccine segment. The increase in authorized share capital will support these growth ambitions.

Risks to watch

Investors should monitor the successful completion of the warrant issuance and the company's ability to execute its ambitious expansion plans, especially its entry into the competitive vaccine market. The company did not recommend any dividend for FY 2025-26, retaining earnings for expansion, which means shareholders will not receive immediate income from dividends.

Peer comparison

While specific peer performance data is not provided in the filing, Chandra Bhagat Pharma's reported growth in revenue and PAT indicates a positive performance relative to its own historical results. The pharma sector in India is highly competitive, and success will depend on effective product launches and market penetration.

Context metrics

• Revenue from Operations FY 2025-26: ₹116.27 crore (vs. ₹88.81 crore FY 2024-25)
• Profit After Tax FY 2025-26: ₹3.05 crore (vs. ₹0.86 crore FY 2024-25)
• Proposed Fund Raise: ₹29.04 crore via 66 lakh warrants at ₹44 per warrant.

What to track next

Investors should keep an eye on the successful allotment of warrants, the company's progress in establishing a new manufacturing facility, and its strategic entry into the vaccine market. Management's ability to execute these plans will be crucial for future performance.